Jim Simons Theseus Pharmaceuticals, Inc. Transaction History

Renaissance Technologies LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$2.12 - $4.18 $308,260 - $607,797	145,406 Added 115.22%	271,600 $1.1 Million
Q3 2023 Nov 14, 2023	BUY	$2.66 - $10.04 $226,084 - $853,339	84,994 Added 206.3%	126,194 $339,000
Q2 2023 Aug 11, 2023	SELL	$7.28 - $11.82 $650,832 - $1.06 Million	-89,400 Reduced 68.45%	41,200 $384,000
Q1 2023 May 12, 2023	BUY	$5.21 - $14.05 $582,478 - $1.57 Million	111,800 Added 594.68%	130,600 $1.16 Million
Q4 2022 Feb 13, 2023	BUY	$4.69 - $8.36 $88,172 - $157,168	18,800 New	18,800 $94,000

1.06M

Ticker THRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,713,400
Description
Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors, which is in Phase I clinical trial. The company also ...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.